Ep 19: Single-dose of neoadjuvant pembro (UPenn study)

Why make the bed? Who needs a mnemonic for washing? In the opening quickfire discussion, James and Sapna get SERIOUS. In this episode, they discuss a paper from Nature Medicine 2019 titled 'Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma.' They explore the significance of the study, which showed that a single dose of preoperative PD-1 blockade can induce complete and major pathologic responses in a subset of patients with resectable melanoma. They also discuss the implications of the study for future research and the challenges of tumor heterogeneity and biomarker testing. Overall, the conversation highlights the potential of neoadjuvant PD-1 blockade in melanoma treatment. Keywords neoadjuvant PD-1 blockade, resectable melanoma, clinical outcomes, complete response, major pathologic response, tumor heterogeneity, biomarker testing Takeaways A single dose of preoperative PD-1 blockade can induce complete and major pathologic responses in a subset of patients with resectable melanoma. The study highlights the potential of neoadjuvant PD-1 blockade in melanoma treatment. Tumor heterogeneity poses challenges in biomarker testing and predicting treatment response. Further research is needed to explore different regimens and durations of neoadjuvant PD-1 therapy. Correlative analysis and in-depth studies are valuable in understanding the mechanisms and outcomes of neoadjuvant therapy. Titles Challenges of Tumor Heterogeneity in Biomarker Testing The Potential of Neoadjuvant PD-1 Blockade in Melanoma Treatment Sound Bites "You know, what are additional doses actually doing? Are they blocking the receptor better? Are they adding to toxicity?" "They gave a dose, they didn't lose resectability on patients, they found that they could actually induce complete response with a single dose of neoadjuvant PD-1." Chapters 00:00 Introduction and Bed-Making 03:04 The Study: Single Dose of Neoadjuvant PD-1 Blockade 06:11 Context and Future Directions of Neoadjuvant Therapy 09:09 Biomarker Testing and Tumor Heterogeneity